ArticleFrontiers in immunology2025
Repetitive transcranial magnetic stimulation alleviates neuropathic pain via microglial polarization by modulating the METTL3/NMDAR2B/NLRP3 pathway.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting Pain and Depression in Alzheimer's Disease: Translational Insights and Emerging Treatments.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Neuropathic pain (NeuP) remains a major clinical condition, and the existing interventions often fail to provide sufficiently satisfactory symptom control. Repetitive transcranial magnetic stimulation (rTMS) has gained attention as a potential non-invasive therapy for NeuP. However, the precise mechanisms underlying the effects of rTMS remain elusive. Objective: This study explores the potential neurophysiological mechanisms of rTMS in NeuP, focusing on its modulation of the methyltransferase-like 3 (METTL3)/ Methods: CCI rats began to receive rTMS treatment once daily 7 days after the operation, and the treatment continued for 4 weeks. Pain and depression-like behaviors were evaluated by measuring the paw-withdrawal mechanical threshold (PWMT), thermal pain-induced paw-withdrawal latency (PWL), sciatic nerve function index (SFI), forced swimming test (FST) results, and new object preference index (NPI). The expression levels of relevant indicators were detected by immunofluorescence and western blot analyses, quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and enzyme-linked immunosorbent assay (ELISA). BV2 microglia were cultured in Dulbecco's modified Eagle medium. After adding agonists and inhibitors of METTL3 and NMDAR2B, the microglia were treated with lipopolysaccharide (LPS; 100 µg/mL) for 12 h. The cells are divided into seven groups: Control (Con), LPS, LPS + magnetic stimulation (MS), LPS + METTL3 inhibition (sh-METTL3), LPS + METTL3 overexpression + magnetic stimulation (LPS+METTL3-OE+MS), LPS + NMDAR2B inhibition (sh-NMDAR2B), and LPS + NMDAR2B overexpression + magnetic stimulation (LPS+NMDAR2B-OE+MS). The expression levels of cell polarization markers, inflammatory factors, and related proteins were detected by methods such as immunofluorescence and western blot analyses, qRT-PCR, and ELISA. Results: rTMS improved pain thresholds (PWMT, PWL, and SFI) and depressive-like behaviors, reduced immobility in the FST, and increased the NPI. It inhibited the levels of the pro-inflammatory markers interleukin (IL)-6, tumor necrosis factor (TNF)-α, NLRP3,TMEM119 and iNOS in the dorsolateral prefrontal cortex (DLPFC), while increasing the expression of IL-10 and Arg1. Moreover, rTMS decreased the expression levels of the M1-type marker CD86 of microglia and increased those of the M2-type marker CD206 and simultaneously decreased the expression of microglia activation marker Iba-1. rTMS simultaneously downregulated METTL3, N6-methyladenosine (m6A), NMDAR2B, and YTH domain-containing family 1 (YTHDF1). In the Conclusion: rTMS can affect the polarization state of microglia and neuroinflammation by regulating the METTL3/NMDAR2B/NLRP3 signaling pathway, thereby improving NeuP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.